Has Roy Phillips, MD received payments from drug or device companies?

Yes. Drug and device makers reported $208,455 in general payments to Roy Phillips, MD across 1,016 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roy Phillips, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roy Phillips, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roy Phillips, MD

Endocrinology, Diabetes & Metabolism · Bel Air, MDNPI 1881699411

Payments from drug & device makers

$208,455in general payments, 2019–2025

Across 1,016 payments — averaging $205.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$107K
Novo Nordisk$37K
Amgen$28K
Boehringer Ingelheim$17K
Abbott$9K
AbbVie$5K
plus $6K from 39 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	265	$106,962
Novo Nordisk	120	$36,729
Amgen(2 entities)	105	$27,662
Boehringer Ingelheim	73	$17,389
Abbott	61	$8,626
AbbVie	110	$5,042
AstraZeneca(2 entities)	28	$593
Sanofi-aventis U.S. LLC	23	$497
Amarin Pharma, Inc.	27	$488
Corcept Therapeutics	20	$425
Xeris Pharmaceuticals, Inc.	15	$305
Insulet Corporation	10	$300
Novartis	14	$280
Amneal Pharmaceuticals LLC	14	$275
Bayer	12	$261
Radius Health, Inc.	9	$228
Cequr Corporation	3	$212
Dexcom, Inc.	9	$189
Lifescan, Inc.	9	$153
Johnson & Johnson	6	$149
Madrigal Pharmaceuticals	5	$148
Merck	10	$141
Tandem Diabetes Care, Inc.	6	$138
Mannkind Corporation	10	$130
Medtronic(2 entities)	7	$126
Almatica Pharma LLC	4	$115
BETA Bionics, Inc.	3	$113
Neurocrine Biosciences, Inc.	4	$98
BD	3	$72
Nevro Corp.	3	$68
Antares Pharma, Inc.	3	$56
Pfizer	3	$56
Recordati_rare_diseases_inc.	3	$52
Valeritas, Inc.	2	$52
Embecta Corp.	2	$47
Amryt Pharma Holdings Ltd	2	$39
Ipsen Biopharmaceuticals, Inc	2	$37
Sequel Med Tech, LLC	2	$34
Ultragenyx Pharmaceutical Inc.	2	$31
Averitas Pharma Inc.	1	$31
IBSA Pharma Inc.	2	$28
Roche Diabetes Care, Inc.	1	$28
Ascendis Pharma Endocrinology Inc	1	$20
Shire North American Group Inc	1	$16
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$12

How this compares

$208,455 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Medicare billing

Part B allowed, 2024

$391,758

Medicare patients

598

Services billed

13,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Bel Air

Jean ParkBaltimore$3.7M
Michael DempseyRockville$2.7M
Ilias SpanakisBaltimore$2.6M
Helena RodbardRockville$2.4M
Daniel GozziSuitland$1.2M
Martin SarkarFrederick$1.1M
Romeu AzevedoCamp Springs$1.1M
Nicholas ArgentoLaurel$1.1M
Philip LevinBaltimore$702K
David BrownRockville$497K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →